StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
August 25, 2026 3:31 AM
Bernstein SocGen Group analyst Jeffrey Walch reiterated an Outperform rating and $376.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
